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a b s t r a c t
Meningiomas (MGs) are the frequent benign intracranial tumors. Their complete removal does
not always guarantee relapse-free survival. Recurrence-associated chromosomal anomalies in
MGs haves been proposed as prognostic factors in addition to the World Health Organisation
(WHO) grading, tumor size and resection rate. The aim of this study was to evaluate the
frequency of deletions on chromosomes in sporadic MGs and to correlate them with the
clinical ﬁndings and tumor behaviour. Along with survival, the tumor recurrence was the main
endpoint. Chromosomal loss of heterozygosity (LOH) was studied. 46 benign MGs were
subjected to the analysis, complete tumor resection was intended and no early mortalities
were observed. Incomplete removal was related to parasagittal location and psammomatous
hisptopathology (p < 0.01). Chromosomal alterations were present in 82.6% of cases; LOH at
22q (67.4%) and 1p (34.8%) were the most frequent and associated with male sex (p = 0.04).
Molecular ﬁndings were not speciﬁc for any of the histopathologic grade. Tumor recurrence (14
of 46) correlated with tumor size (≥35 mm), LOH at 1p, 14q, coexistence of LOH at 1p/14q, 10q/
14q, 'complex karyotype' status (≥2 LOHs excluding 22q), patient age (younger <35), and
Simpson grading of resection rate (≥3 of worse prognosis). The last 3 variables were indepen-
dent signiﬁcant prognostic factors in multivariate analysis and of the same importance in
recurrence prediction (Receiver Operating Characteristic curves comparison p > 0.05). Among
the cases of recurrence, tumor progression was observed in 3 of 14. In 2 cases, LOH on 1p and/or
coexistence of LOH 1p/14q correlated with anaplastic transformation.
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noses and the extent of resection.
n % or ratio
Demographics
Sex (female:male) 33:13 Ratio:2.54
Age [mean  SD
median, min–max]
51.1  12.9
50 (20–80)
Location
Supra-/infratentorial 38:8 ratio:4.75
Convexity 25 54.3%
Parasagittal or falx 15 32.6%
Cranial base 21 45.7%
Sphenoid 13 28.3%
Pyramid 5 10.9%
Size (mm)
<35 4 8.7%
35–55 11 23.9%
>55 31 67.4%
Simpson grading
1 26 56.5%
2 15 32.6%
3 4 8.7%
4 1 2.2%
Histopathology
Transitional 24 52.17%
Fibroblastic 10 21.7%
Meningothelial 9 9.57%
Psammomatous 3 6.52%1. Introduction
According to the recent reports (2007–2011 USA registry),
meningiomas (MGs) are the most frequently diagnosed brain
tumor (36.1%), exceeding half of all intracranial benign tumors
(53.7%) [1]. A MG is a frequent incidental ﬁnding in magnetic
resonance imaging (MRI) of the head, but is revealed in only 2%
of autopsies [2,3]. To date, the etiology of these tumors has not
been sufﬁciently explored. Researchers attempted to use
molecular biology to explain the recurrence phenomena of a
completely removed MG. The criteria of the diagnosis of Grade
1–3 MG (respectively benign, atypical and malignant) were
based on clinicopathological correlations made by the World
Health Organisation (WHO) [4,5]. The 2007 revision of the WHO
classiﬁcation identiﬁed 14 heterogeneous histopathological
subtypes [6]. According to WHO 80% of all MGs are slowly
growing Grade 1 tumors [7]. Whereas the Grade 2 or 3 are rarely
diagnosed. Moreover, it has been suggested that 17–35% of
Grade 2 and 54–70% of Grade 3 progress from benign subtypes
[8,9]. The WHO grading of MGs remains controversial,
nonetheless it has facilitated estimating patient management
[10]. Parallel to the resection rate, the WHO classiﬁcation is still
regarded as the most potent prognosis-associated factor
[10,11].
Almost 40% of the totally removed Grade 2 tumors relapse,
comparing to only 5% of Grade 1 MGs [12]. However, the
diagnosis of one of nine subtypes of benign MG (called Grade 1,
non-cancerous) does not preclude its worse clinical behaviour
in some patients [13]. Finally at least a quarter of patients
harbouring a benign MG experience a tumor relapse within
20 years [14]. Therefore, some prognosis-related factors have
been proposed to identify a clinically aggressive subset of
benign MGs: familial occurrence, patient age, tumor location,
Ki-67/MIB-1 labelling index, telomerase activity, proliferating
cell nuclear antigen [15–17]. Recently the molecular biology
has attempted to explain the recurrence phenomena of a
completely removed MG [10,18–20].The milestone was the
identiﬁcation of the NF2 gene on the long arm of chromosome
22 (22q12.2) that is responsible for the production of merlin (a
cytoskeletal protein). Mutation or loss of NF2 is associated with
the multiple tumor occurrence and is found in up to 70% of
sporadic MGs [21,22]. Since 22q was established the most
frequent aberration in MGs, authors focused on cytogenetic
proﬁling of MG tumorigenesis or progression. A broad array of
the loci was postulated, including 1p, 3q, 6q, 9p, 9q, 10p, 10q,
14q, 14p, 18p, 18q and 22q [10,20,23,24]. Moreover, single
nucleotide polymorphism (SNP) demonstrated loss of hetero-
zygosity (LOH) on several loci within one cytoband in MGs [21].
Surprisingly, the investigators sparsely focused on the
correlation of molecular ﬁndings with clinical data. Benign
tumors with known genomic status were rarely followed-up,
thus we still are not certain of the relapse-associated
chromosomal aberrations [18,20,25–27]. In clinical perspective,
the disease-free survival is actually the most crucial outcome
measure. The estimation of relapse-speciﬁc genomic land-
scape of MGs is strongly desired [18]. A prognosis based on
molecular and histopathological ﬁndings is believed to prompt
a decision-making process tailored to each individual patient
[20].2. Materials and methods
2.1. Study design
The aim of the study was to correlate the recurrence status and
time to relapse with chromosomal alterations in sporadic
Grade 1 MGs. The analysis included clinical data such as age,
sex, tumor location and rate of recurrence. Multivariate
analysis was used to bring reliable molecular recurrence-related
prognostic factors.
2.2. Patients
Tumor tissues were obtained from patients presenting with
non NF1/NF2-related intracranial MG. All consenting patients
were managed operatively at the Neurosurgery Department
(coded for peer review process) from 1999 to 2007. Intent-to-
treat patient selection was applied; complete resection was
intended in all cases and the Simpson grading was used for
assessing the extent of tumor removal [28]. The study group
consisted of 46 patients with benign (WHO Grade 1) sporadic
MGs. The demographics are presented in Table 1. Pre- and
postoperative imaging was evaluated, but was not standar-
dised throughout the study (either computer tomography or
MRI was performed based on the accessibility). The details of
the surgical techniques performed are beyond the scope of this
article purpose. Baseline and postoperative neurological status
was not evaluated. Postoperative radiotherapy was not
offered. All patients were followed-up either by outpatient
clinic visits, mail, e-mail or phone.
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Tumor samples were collected intraoperatively for the
standard histopathological examination and for the molecular
analysis.
For the purpose of the molecular analysis, samples were
stored at 20 8C. The genomic DNA was isolated from frozen
tumor tissues and the corresponding peripheral blood leuko-
cytes using a phenol–chloroform extraction protocol. Further
quantiﬁcation and analysis with respect to protein content
and purity was performed. The markers were selected by using
the NCBI database; paired normal and tumor DNA samples
were analysed for LOH using 24 microsatellite markers
obtained from HVD Holding AG (Ebersberg, Germany). The
following polymorphic loci were tested: D1S508, D1S199, D1S197,
D1S162, D9S156, D9S162, D9S319, D9S1748, D10S197, D10S209, D10S587,
D10S1709, D14S292, D14S1010, D18S481, D22S257, D22S258, D22S268,
D22S298, D22S303, D22S449, D22S609, D22S1150, and D22S1163. The
polymerase chain reaction (PCR) was performed under
standard conditions, the products were then electrophoresed
on 6% denaturing polyacrylamide gel containing 7 mmol/L of
urea and visualized using a LiCor automatic sequencer (LiCor
Biotechnology, Lincoln, NE, USA). A >50% reduction of
intensity in the tumor lane compared to the corresponding
blood lane was regarded as LOH. All samples with LOH were
conﬁrmed by repeated analysis.
Histopathological examination was performed; tumor
samples were put in a 4% solution of buffered formaldehyde;
dehydrated after 10–24 h of ﬁxation, cleared and impregnated
with parrafﬁn in tissue processor and embedded in parafﬁn
blocks. Slices of 4 mm thickness were made and placed on
microscope slides, stained by hematoxylin and eosin using an
automatic stainer, then covered with coverglasses. After the
initial histopathologic evaluation, immunostains with anti-
bodies to progesterone receptor, epithelial membrane antigen
(EMA) and MIB-1 were performed. Tumors were classiﬁed
according to the WHO criteria (2002 and 2007 revision) [6,13].
2.4. Statistical analysis
The Chi-square with or without Yates correction for continui-
ty, Fisher test, t-test or Mann–Whitney U test were used
for testing statistical hypotheses. The independent MGTable 2 – Distribution of loss of heterozygosity on determined 
presented. Statistically significant correlation in bold. LOH – lo
Sex 
Entire group
(n = 46)
Females
(n = 33)
Males
(n = 13)
p Meni
LOH at n % of column (n; % of column) 
1p 16 34.8% 8; 24.2% 8; 61.5% 0.04 4
9p 3 6.5% 2; 6.0% 1; 7.7% 0.64 0
10q 6 13.0% 2; 6.1% 4; 30.8% 0.07 0
14q 13 28.0% 9; 27.7% 4; 30.8% 0.90 4
18p 1 2.2% 1; 3.0% 0; 0.0% 0.63 0
22q 31 67.4% 25; 75.8% 6; 46.1% 0.11 3recurrence-associated factors were obtained by logistic re-
gression in stepwise fashion. Odds ratios (ORs) were provided
with 95% conﬁdence interval (CI). Area under (AUC) receiver
operating characteristic (ROC) curve was calculated for
signiﬁcant factors in multivariate analysis. GraphPad Prism
v6.07 (GraphPad, La Jolla, CA, USA) and Statistica v12.0
(StatSoft, Tulsa, OK, USA) were applied for the calculations.
A p value <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Outcome
There were no early mortalities either related to the initial
surgery. All 4 small and 72.7% (8 of 11) of medium MGs were
excised completely (Simpson grade 1). Only 45.2% (14 of 31) of
large tumors were resected totally with attached dura mater.
However, the tumor size did not inﬂuence the resection rate
(Chi-square 10.5, p = 0.10). Convexity and cranial base MGs had
a similar resection rate (Chi-square/Yates 2.4, p = 0.49),
likewise infra and supratentorial tumors (Chi-square/Yates
0.6, p = 0.89). However, parasagittal (falx) tumor location
correlated to its incomplete removal (Simpson grade ≥3). Of
note, 3 of 15 (20.0%) parasagittal MGs were partially resected
and 2 of 31 (6.5%) those occupying other location (Chi-square
17.9, p < 0.01). All ﬁbroblastic (n = 10), almost every menin-
gothelial (8 of 9; 88.9%) or transitional MG (22 of 24; 91.7%) was
totally removed, while only 1 of 3 (33.3%) of psammomatous
histopathology were (Chi-square 17.8, p = 0.04). Simpson
grading did not correlate with the side of tumor (Chi-square
3.4, p = 0.76) or sex (Chi-square/Yates 0.63, p = 0.89).
3.2. Genetic proﬁle
Chromosomal alterations among the determined set of loci
were present in 38 MGs (82.6%). The most frequent alteration
was LOH at 22q, following 1p and 14q. Male sex signiﬁcantly
predisposed to LOH at 1p. No LOHs were speciﬁc for any of
histopathology (Table 2).
No speciﬁc chromosomal localization of LOH was associat-
ed with tumor localization nor its primary size (p > 0.05). Only
tumors >35 mm in diameter harboured mutation on 10q (n = 6)cytobands. A correlation with sex and histopathology was
ss of heterozygosity.
Histopathology
ngothelial Fibroblastic Mixtum Psammomatous P
(n; % of column)
; 44.4% 3; 30.0% 9; 37.5% 0; 0.0% 0.54
; 0.0% 2; 20% 1; 4.2& 0; 0.0% 0.26
; 0.0% 1; 10.0% 5; 20.8% 0; 0.0% 0.37
; 44.4% 3; 30.0% 6; 25.0% 0; 0.0% 0.48
; 0.0% 1; 10.0% 0; 0.0% 0; 0.0% 0.30
; 33.3% 9; 90.0% 17; 70.8% 2; 66.7% 0.07
Fig. 2 – Venn diagram demonstrating the influence of
chromosomal anomalies on the meningioma recurrence.
Tumors presenting with a selected chromosomal
alterations or their coexistence are stratified for recurrent
(black/red, black – insignificant, red – significant
comparisons) and non-recurrent meningiomas (grey bar).
Fig. 1 – Number of patients with total number of altered
chromosomes.
Light red line – 22q anomaly was included, dark red line –
without 22q.
LOH – loss of heterozygosity.
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Of note, none of smaller MGs had LOH at 10q. Patient age did
not correlate with any LOH (p = 0.16–1.00).
Excluding LOH at 22q, 11 tumors (23.9%) had LOH on at least
two cytobands (named herein 'complex karyotype'). The mean
number of chromosomal alterations was 1.5 (median 1,
maximum LOH at 6 chromosomes) (Fig. 1).
'Complex karyptype' was more frequent in males (6/13 46.1%
vs. 5/33 15.2%; p = 0.07) and signiﬁcantly more frequent for MGs
located parasagittally (7/15 46.7% vs. 4/31 12.9%; p = 0.03).
Neither age (p = 0.72), histopathology (p = 0.68) or Simpson
grade (p = 0.26) associated with LOH occurrence.
3.3. Tumor recurrence
Mean observation time to the ﬁrst relapse after successful
surgery was 5.7 years (16 months–13 years). 19.6% of patients
(9/46) were followed for less than 30 months. In the time of
observation tumor relapsed in 14 patients (30.4%), 9 of whom (9
of 14; 64.3%) experienced a second relapse. In the recurrence
group, mean relapse-free survival was 31.5 months (median
25.5; 9 months–6 years). Slightly more males experienced MG
relapse (7/13 53.9% vs. 7/33 21.2%; p = 0.07). Convexity location
had A tendency to recur was noted in the convexity location,
though it was not statistically signiﬁcant (11/25 44.0% vs. 3/21
14.3%; p = 0.06). Supra/infratentorial location (Chi-square/
Yates 0.1, p = 0.96), cranial fossa (Chi-square 3.8, p = 0.42), side
of the body (Chi-square 0.0, p = 0.99) as well as MG histopa-
thology (Chi-square 0.7, p = 0.88) did not demonstrate inﬂu-
ence on the recurrence. MIB1 labeling index was evaluated in
less than a half of cases thus not studied. 0 (0.0%), 1 (9.1%) and
13 (41.9%) of small, medium and large tumors relapsed
respectively (Chi-square 6.1, p = 0.05). As hypothetized, the
rate of resection had an impact on the recurrence: 29.3% (12 of
41) of completely removed MGs (Simpson grade ≤2) versus
40.0% (2 of 5) of grade ≥3 relapsed (Chi-square 11.7, p < 0.01).
Younger patients experienced tumor recurrence more often,
as mean age in the recurrence group was 54.1 (SD  12.9) and in
the non-recurrence group was 44.1 (SD  10.1) (Z statis-
tics = 2.6; p < 0.01).The presence of LOH at any of the examined cytobands was
not associated with the recurrence (Chi-square/Yates 2.7,
p = 0.10). The analysis of a single aberration revealed that only
LOH at 1p, 14q as well as 'complex karyotype' (LOH at more than 2
loci) was related to the tumor recurrence. The greater number
of chromosomes was damaged, the greater was the risk of
recurrence; 8 of 14 (57.1%) recurrent tumors had complex
karyotype (Fig. 2, Table 3).
Interestingly, 2 of the 7 tumors (28.6%) relapsed in the same
location and 6 of 7 (85.6%) that relapsed in other location had
complex karyotype (Fisher exact test 0.4, p = 0.38).
Summarising the signiﬁcant univariate analyses of relapse-
associated factors, there were 5 genetic variables: 1p, 14q,
complex karyptype (including coexistence of 1p/14q and 10q/
14q), total number of damaged chromosomes (excluding 22q)
as well as 3 other variables: size, Simpson grading, and patient
age. In logistic regression (model Chi-square 24.6) only 3
factors independently and signiﬁcantly inﬂuenced the recur-
rence behaviour: age (OR = 0.9; 95%CI: 0.8–1.0; p = 0.03), complex
karyotype (OR = 27.2; 95%CI: 3.3–223; p < 0.01) and resection rate
(Simpson grading) (OR = 4.8; 95% CI: 1.4–16.8; p = 0.01). All of the
above 3 factors had a comparable impact on the benign MG
recurrence (ROC curves comparison: p < 0.01) (Fig. 3).
Area under curves (AUC) of the following factors: complex
karyotype AUC = 0.74; 95%CI: 0.59–0.86, Simpson grading
AUC = 0.73; 95%CI: 0.58–0.85, patient age AUC = 0.74; 95%CI:
0.59–0.85.
Concerning the 14 patients who experienced tumor recur-
rence, time to relapse (in other words relapse-free survival) was
analysed in terms of various factors (LOH, demographics,
tumor location, rate of resection and histopathology).
Table 3 – The comparison of genetic profile of meningio-
mas in patients with and without relapse. Statistically
significant correlations in bold.
Recurred
(n = 14)
Non-recurred
(n = 32)
p
LOH at (n; % of column)
1p 9; 64.3% 7; 21.9% 0.01
9p 2; 14.3% 1; 3.1% 0.45
10q 3; 21.4% 3; 9.4% 0.52
14q 8; 57.1% 5; 15.6% 0.01
18p 1; 7.1% 0; 0.0% 0.67
22q 9; 64.3% 22; 68.8% 0.96
Complex karyotype 8; 57.1% 3; 9.4% <0.01
1p/10q 3; 21.4% 1; 3.1% 0.14
1p/14q 7; 50.0% 2; 6.3% <0.01
1p/22q 5; 35.7% 5; 15.6% 0.26
10q/14q 3; 21.4% 0; 0.0% 0.04
10q/22q 2; 14.3% 2; 6.3% 0.74
14q/22q 3; 21.4% 5; 15.6% 0.96
Number of damaged
chromosomes
(mean  SD)
Including 22q 1.6  1.4 0.5  0.8 0.02
Excluding 22q 2.2  1.5 1.2  0.9 0.01
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signiﬁcant impact.
3.4. Tumor progression
Among all cases of MG recurrence, there were 3 (21.4%; 3 of 14)
that progressed to higher grade according to WHO classiﬁca-
tion. In Patient 1 the tumor progressed to atypic and then to
anaplastic MG. Patient 2 had a primary transitional MG, but on
it relapsed as atypic. Patient 3 had a Grade 1 (meningothelial)
recurrent tumor, whereas the second relapse was diagnosed as
atypic MG. The molecular proﬁle of the progressed tumors wasFig. 3 – Comparison of Receiver Operating Characteristic
(ROC) curves between significant markers of benign
meningioma recurrence.the same in 2 cases, whereas in Patient 1 the additional 1p
mutation was noted upon the ﬁrst relapse (Fig. 4).
4. Discussion
Leaving an apparently cured patient with Grade 1 MG
unattended may be deletoriuos as the tumor can relapse.
Irrespective of the WHO classiﬁcation, two factors are
undisputedly regarded as responsible for the recurrence –
tumor size and the resection rate [29]. Considering only benign
MGs, as in our series, a complete removal of the tumor mass
could be achieved at least in half of patients. However, the
neurosurgeons' self-assessment remains unreliable. In our
series partially resected MGs were followed up by imaging
without radiotherapy. Finally, 5% of the totally resected
tumors recur [12], but almost 20% recur if observed for 20 years
[13,14,30]. The resection rate correlated with recurrence rate in
our series.
Younger patients are more prone to develop tumor
recurrence, which can be connected with a longer survival
time, but not elucidated. In our study, the multivariate
analysis pointed to age as an independent and statistically
signiﬁcant factor responsible for the relapse status. Linsler's
results does not support our ﬁndings even though he
incorporated over hundred patients [31]. According to the
Domingues series (302 cases), older patients experience longer
relapse-free survival [20].
The third marker of recurrence in our study was the tumor
size. One explanation is that more advanced technical skills
are required to completely remove the larger tumor and
therefore leaving a remnant is more probable. We proved that
the size of the tumor did not inﬂuence the resection rate.
Tumor location correlated with the resection rate, but also
relates to the recurrence rate itself. MGs originating at the
cranial base recur more often than those of other locations
[20,32]. In our sample, the recurrence of the convexity MGs was
insigniﬁcantly more frequent than in cranial base tumors.
Molecular proﬁling is a recent and considered as powerful
tool in explaining tumorigenesis of various brain tumors
[10,33]. The aberration of chromosome 22 or mutation of NF2
(22q12.2) are the most commonly cited cytogenetic markers in
MGs [34]. NF2 mutation is most frequent in ﬁbroblastic,
transitional and psammomatous histopathology [35]. In our
series, 2/3 of tumors presented with LOH at 22q, which was the
most frequent chromosomal aberration, though not associat-
ed with any particular histopathology. On the epigenetic level,
the mutation or incorrect expression of the candidate genes
(including, but not limited to, MN1, INI1, TIMP-1, TIMP3, p16,
BCR, BAM22) was suspected in MG pathogenesis [31,36].
However, the above ﬁndings still show a limited prognostic
value for patients harbouring Grade 1 MG. Genetic changes
may bring better understanding of the relapse of completely
removed benign tumors [23]. Recent studies consider the
analysis of chromosomal LOH as the most crucial part of
genetic evaluation in MGs [10,20,21].
For years the histopathological classiﬁcation has been
regarded as the most accurate parameter in the prognostica-
tion of these tumors. However, both the clinical and prognostic
value of WHO grading is limited in cases of benign MGs
Fig. 4 – The molecular characteristic of the 3 patients in who tumor progression was observed. The initial computer
tomography (CT, axial plane image) of the Patient 1 (red tick) was presented (1) and axial plane CT at the time of tumor
relapse (2) (atypic histopathology and additional 1p mutation). Second progression (3) magnetic resonance imaging (axial and
coronal plane images) demonstrated sagittal sinus, bone and brain invasion. The coexistence of loss of heterozygosity at 1p/
14q was marked.
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number of relapses after a seemingly successful removal
among all MGs is the highest for benign histopathologies [26].
Moreover, some Grade 1 tumors behave more aggressively,
similarly to atypic or anaplastic MGs. These ﬁndings demon-
strate the need to identify additional recurrence-associated
biomarkers, speciﬁc for benign tumors. Predicting the worst
clinical scenario could streamline a tailored therapy.
Following 22q, the anomaly of 1p is the most frequent
chromosomal aberration in sporadic MGs. However, opposite
to 22q, LOH on 1p is considered as the most inﬂuencial
recurrence-associated chromosomal change [21,31]. Except for
ELAVL4, the presence of any other suppressor gene among 1p
was suggested, but as of yet was not sufﬁciently proven [38].
The expression of ELAVL4 was lower in males, explaining the
higher recurrence rate in males [36]. LOH on 1p and male sex
both correlated with tumor recurrence in univariate statistics
in our study, which can indirectly conﬁrm the deleterious role
of ELAVL4 mutation.
Among the determined loci, LOH on 9p, 10q and 18p was
not related to the aggressive behaviour of a benign MG. Other
cytogenetic investigations described the role of 9q, 10q and
18p in MG progression and which are a characteristic ﬁnding
in anaplastic histopathology [38]. The alteration of 10q is
linked with the PTEN mutation (10q23.3), characteristic for
Cowden syndrome [38], but rare in MGs. Larger tumors in our
series displayed mutations on 10q more often. On the other
hand, the coexisting LOH on 10q and 14q was a signiﬁcant
marker of recurrence in our series. The mutation or
hypermetylation ofNDRG2 and MEG3 both a located on 14q
were proposed in MG progression and recurrence [38]. Most of
clinical studies conﬁrmed 14q as a prognostic indicator for
recurrence in Grade 1 tumors [20,38,39], as shown in our
study.Opposite to the results of the multivariate analysis, a
variety of cytogenetic anomalies demonstrated the impact on
the tumor recurrence in our series. LOH on 1p, 14q, 'complex
karyotype,' combined LOH on 1p/14q, 10q14q as well as total
number of aberrations (excluding the most common LOH –
22q) were signiﬁcant in univariate comparisons. Domingues
et al. performed an analysis similar to ours and out of many
the numerous single prognostic factors selected only the
'complex karyotype', tumor location, tmour size and patient
age as the best combination of independent variables for
predicting relapse-free survival only [20]. These prognostic
factors were incidental in our ﬁndings, except for the Simpson
grade of resection. Domingues et al. created a tailored scale of
prognostic importance which can be applied to any single
patient post hoc. According to their ﬁndings, the role of a
molecular biology in predicting a MG recurrence seems crucial,
but likewise in our series it is limited to the number of altered
loci. The statistical methodology applied in both studies
(Domingues et al. and ours) revealed that univariate compari-
son seems valid, unless multivariate analysis is performed
[20]. Multivariate analysis is a goal in the recurrence.
Unfortunately Pﬁsterer et al. [19] contradicted all of the
above conclusions. He demonstrated that a regional variability
of distribution in chromosomal changes exists in a single MG.
For example, only 20% of benign MG presented with a
homogeneous 14q aberration.
Our study did not aim to investigate the molecular pattern
of tumor progression. Out of 14 relapsed tumors, 3 exhibited
histopathological progression. The molecular ﬁndings
revealed that acquired loss of genetic material on 1p and
coexistence of LOH on at 1p/14 lead to anaplastic transforma-
tion. These ﬁndings, based only on 3 progressed samples,
support the deleterious role of mutation on 1p in progression
of MG [20,39].
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 3 9 5 – 4 0 2 401In sum, the aggressive phenotype of a benign MG is
certainly correlated with its molecular status. Popular cyto-
bands, including 1p, 14q and their coexistence, are recurrence-
speciﬁc genomic alterations.
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